Bacillus Calmette–Guérin (BCG) vaccine is a vaccine primarily used against tuberculosis. BCG also has some effectiveness against Buruli ulcer infection and other nontuberculous mycobacteria infections. The vaccine was originally developed from Mycobacterium bovis, which is commonly found in cows. It is on the World Health Organization’s List of Essential Medicines.
About BCG vaccine in brief
Bacillus Calmette–Guérin (BCG) vaccine is a vaccine primarily used against tuberculosis. BCG also has some effectiveness against Buruli ulcer infection and other nontuberculous mycobacteria infections. Rates of protection against tuberculosis infection vary widely and protection lasts up to twenty years. The vaccine was originally developed from Mycobacterium bovis, which is commonly found in cows. The BCG vaccine was first used medically in 1921. It is on the World Health Organization’s List of Essential Medicines. As of 2004, the vaccine is given to about 100 million children per year globally. The most controversial aspect of BCG is the variable efficacy found in different clinical trials. There are differences in effectiveness, depending on region, due to factors such as genetic differences in the populations, changes in environment, exposure to other bacterial infections, and conditions in the lab where the vaccine was grown. A reactive tuberculin skin test is usually carried out before administering BCG. A single intradermal injection is given as a single injection at the insertion of the deltoid injection bag. If the injection is accidentally given accidentally, a local abscess then subcutaneously, then a severe abscess may form. An abscess can sometimes require treatment with antibiotics, but it could always require immediate treatment without treatment. If an abscess does form, it could cause severe damage to the vital organs, causing severe damage. If it does not, then the abscess must be treated with antibiotics immediately, otherwise it could spread to other parts of the body.
If this happens, the patient may need to be admitted to the hospital for treatment. It can cause a false positive Mantoux test, although a very high-grade reading is usually due to active disease. If a patient is admitted to hospital with abscessed abscesses, then they may need immediate treatment. This is usually done at the hospital where the patient has been admitted to be treated for bladder cancer. By 2014 there were more than eight different considered agents or strains used for the treatment of non–invasive cancer. A biosimilar test isusually carried out prior to administering the BCG skin test. The skin test does not indicate any risk of local inflammation due to the risk of severe inflammation and scarring; it is contraindicated in certain people who have IL-12 receptor pathway defects. If you are pregnant, it is not safe for use during pregnancy. You should not use BCG during pregnancy, as it can cause serious side effects such as severe scarring and local inflammation. It has been the standard of care for patients with bladder cancer since 1977. It’s still extensively used even in countries where efficacy against pulmonary tuberculosis is negligible. It reduces infections by 19–27% and reduced progression to active TB by 71%. BCG seems to have its greatest effect in preventing miliary TB or TB meningitis, so it is still extensively use even in nations where efficacy is negligible, such as the UK.